The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy
Open accessAbstract
Vascular endothelial growth factor (VEGF) is a potent promoter of angiogenesis involved in a wide variety of physiologic processes. Intravitreal injections targeting VEGF have transformed the treatment of neovascular retinal diseases. Currently, there are four anti-VEGF agents in use: bevacizumab, ranibizumab, pegaptanib, and aflibercept. The success and frequency of anti-VEGF therapy have made the ocular safety profile of these agents of vital importance. This paper focuses on sterile endophthalmitis. In this paper, we compare the incidences of posttreatment sterile endophthalmitis among the four agents, review the mechanism of actions, and discuss the most prevalent hypotheses leading to sterile endophthalmitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fundamentally, we must acknowledge eye contains immune-privileged sites with the potential for unique immune-related responses [83].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [83]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687 · cited 3×
“VEGF165 has properties of both the diffusible and bound form of VEGF [1].”
BackgroundInfluentialRanibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Investigative Ophthalmology and Visual Science
Frey, C. (2010) · Cited by 3,350
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588
Papadopoulos, N., Martin, J., Ruan, Q., Rafique, A., Rosconi, M. P., Shi, E., Pyles, E. A., Yancopoulos, G. D., Stahl, N., & Wiegand, S. J. (2012) · Angiogenesis · doi:10.1007/s10456-011-9249-6 · Cited by 1,037
Rosenfeld, P. J., Moshfeghi, A. A., & Puliafito, C. A. (2005) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/1542-8877-20050701-14 · Cited by 904 · cited 1×
“Hindawi Publishing Corporation Mediators of Inflammation Volume 2013, Article ID 943409, 6 pages http://dx.doi.org/10.1155/2013/943409”
BackgroundInfluentialRegillo, C. D., Brown, D. M., Abraham, P., Yue, H., Ianchulev, T., Schneider, S., & Shams, N. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.10.004 · Cited by 858
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Wordsworth, S., & Reeves, B. C. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.04.015 · Cited by 781
Research works printed but not linked: 5
- 2012, Ophthalmic Surgery Lasers Imaging, 43, e47
- 10.3928/15428877-20110603-04 · DOI · Paper page
- 2013, Ophthalmology, 120, 1100.5
- 1997, Journal of Interferon and Cytokine Research, 17, S15
- 1987, Laboratory Investigation, 56, 583
Cited by
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Pharmacokinetic aspects of retinal drug delivery
del Amo, E. M., Rimpelä, A.-K., Heikkinen, E., Kari, O. K., Ramsay, E., Lajunen, T., Schmitt, M., Pelkonen, L., Bhattacharya, M., Richardson, D., et al. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.12.001 · Cited by 693
Wang, X., Fan, W., Li, N., Ma, Y., Yao, M., Wang, G., He, S., Li, W., Tan, J., Lu, Q., et al. (2023) · Genome Biology · doi:10.1186/s13059-023-02931-y · Cited by 288
“Repeated intraocular injections may lead to various adverse effects [7].”
BackgroundOcclusive Retinal Vasculitis Following Intravitreal Brolucizumab
Witkin, A. J., Hahn, P., Murray, T. G., Arevalo, J. F., Blinder, K. J., Choudhry, N., Emerson, G. G., Goldberg, R. A., Kim, S. J., Pearlman, J., et al. (2020) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126420930863 · Cited by 183
“(%) White Black 24 (96) 1 (4) Location, No.”
BackgroundInfluentialErratum: Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.86 · Cited by 163
Metadata
- Authors
- Agrawal, S., Joshi, M., & Christoforidis, J. B.
- Affiliations
- Banner - University Medical Center Tucson (US)
- Corresponding author
- Christoforidis, John B.
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2013
- Volume
- 2013
- Pages
- 1-6
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- PMC
- PMC3836427
- OpenAlex
- W2022562553
- Cited by
- 83
- References
- 55
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 11 · 2023: 5 · 2022: 6 · 2021: 9 · 2020: 8 · 2019: 7 · 2018: 5 · 2017: 5 · 2016: 7 · 2015: 8 · 2014: 2
- FWCI
- 0.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Mediators of Inflammation (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- vitreous inflammation, sterile endophthalmitis, anti-VEGF therapy, intravitreal injection, bevacizumab, ranibizumab, pegaptanib, aflibercept, vascular endothelial growth factor, eye safety, pathogenesis
- MeSH terms
- Bevacizumab, Ranibizumab, Humans, Infant, Newborn, Inflammation, Endophthalmitis, Recombinant Fusion Proteins, Retinal Diseases, Risk, Vitreous Body, Angiogenesis Inhibitors, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Aptamers, Nucleotide, Intravitreal Injections, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy. https://app.cochat.ai/papers/10.1155/2013/943409
- The paper
- Agrawal, S., Joshi, M., & Christoforidis, J. B. (2013). Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy. Mediators of Inflammation. https://doi.org/10.1155/2013/943409
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.